Search Result

Results for "

T lymphoblastic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Antibiotic (2) Apoptosis (13) Bcl-2 Family (1) Bcr-Abl (5) Calcium Channel (2) Caspase (1) CD19 (2) CD3 (1) CD47 (1) CDK (1) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Metabolite (2) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (1) Glucocorticoid Receptor (1) Histone Acetyltransferase (1) Histone Demethylase (3) HSP (1) HSV (1) IFNAR (1) Interleukin Related (2) JAK (1) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) Molecular Glues (1) Notch (4) Nucleoside Antimetabolite/Analog (2) p38 MAPK (1) PARP (2) PD-1/PD-L1 (3) PI3K (1) PROTACs (7) Reactive Oxygen Species (ROS) (1) Reference Standards (2) RIP kinase (1) SHMT (1) Src (3) STAT (1) Thrombopoietin Receptor (1) TNF Receptor (1) Transmembrane Glycoprotein (2) γ-secretase (2)
By Research Areas:	Cancer (44) Infection (1) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (3)

By Targets:

AMPK (1)

Antibiotic (2)

Apoptosis (13)

Bcl-2 Family (1)

Bcr-Abl (5)

Calcium Channel (2)

Caspase (1)

CD19 (2)

CD3 (1)

CD47 (1)

CDK (1)

Discoidin Domain Receptor (1)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Drug Metabolite (2)

E1/E2/E3 Enzyme (1)

Epigenetic Reader Domain (1)

Glucocorticoid Receptor (1)

Histone Acetyltransferase (1)

Histone Demethylase (3)

HSP (1)

HSV (1)

IFNAR (1)

Interleukin Related (2)

JAK (1)

Microtubule/Tubulin (3)

Mitochondrial Metabolism (1)

Molecular Glues (1)

Notch (4)

Nucleoside Antimetabolite/Analog (2)

p38 MAPK (1)

PARP (2)

PD-1/PD-L1 (3)

PI3K (1)

PROTACs (7)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

RIP kinase (1)

SHMT (1)

Src (3)

STAT (1)

Thrombopoietin Receptor (1)

TNF Receptor (1)

Transmembrane Glycoprotein (2)

γ-secretase (2)

By Research Areas:

Cancer (44)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9963

Blinatumomab 2 Publications Verification bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-13701

Nelarabine 3 Publications Verification 506U78; GW 506U78; Nelzarabine	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL) .

HY-176244

KI-TOX-A3	Histone Acetyltransferase	Cancer
KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC₅₀ of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8 ⁺ T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL .

HY-N0097A

9-β-D-Arabinofuranosylguanine AraG	Drug Derivative	Cancer
9-β-D-Arabinofuranosylguanine is a Guanosine (HY-N0097) analog and shows high affinity for deoxyguanosine kinase (dGK) with a K_m of 8.0 μM. 9-β-D-Arabinofuranosylguanine can be used for the research of T-cell lymphoblastic disease .

HY-134978A

(+)SHIN2 2 Publications Verification	SHMT	Cancer
(+)SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor, whose target can be traced with ¹³C-serine. (+)SHIN2 increases survival in NOTCH1-driven mouse primary acute lymphoblastic leukemia (T-ALL) in vivo with a synergistic effect with Methotrexate (HY-14519) . (+)SHIN2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14174

MRK-560 4 Publications Verification	γ-secretase	Neurological Disease Cancer
MRK-560, a chemical probe, is an orally active, brain barrier-penetrated γ-Secretase inhibitor, reducing Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL) .

HY-P99650

Grisnilimab WT1	Transmembrane Glycoprotein	Cancer
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .

HY-161828

JWZ-5-13	PROTACs CDK	Cancer
JWZ-5-13 is a CDK7 PROTAC degrader. JWZ-5-13 inhibits the proliferation of cancer cells. JWZ-5-13 is applicable to the research of ovarian cancer, diffuse large B-cell lymphoma, acute T-lymphoblastic leukemia and non-small cell lung cancer .

HY-115463

EB-3D 2 Publications Verification	AMPK Apoptosis	Cancer
EB-3D is a potent and selective choline kinase α (ChoKα) inhibitor, with an IC₅₀ of 1 μM for ChoKα1. EB-3D exerts effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum stress and lipid metabolism. EB-3D exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines. Anti-cancer activity .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210 ^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-171178

DK2403	p38 MAPK	Cancer
DK2403 (compound 25) is a MAP2K7 inhibitor (IC₅₀= 0.01 μM). DK2403 can effectively inhibit MAP2K7 without significantly disrupting the larger kinase group and can be used to study childhood T-cell acute lymphoblastic leukemia .

HY-14572

PR-104A SN 27858	DNA Alkylator/Crosslinker Drug Metabolite	Cancer
PR-104A (SN 27858) is the alcohol metabolite of phosphate proagent PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity . PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL) .

HY-169789

PKN3-IN-1	PI3K	Metabolic Disease Cancer
PKN3-IN-1 (compound 16) inhibits PKN3 (serine/threonine protein kinase 3) and GAK (cyclin G-associated kinase) with IC₅₀ of 0.014 μM and K_i of 0.0044 μM respectively. PKN3-IN-1 is a potential tool compound to study the cell biology of PKN3 and its role in pancreatic and prostate cancer and T-cell acute lymphoblastic leukemia .

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	DNA/RNA Synthesis	Others Cancer
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .

HY-164466

CAD204520	Calcium Channel Notch	Cancer
CAD204520, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 can be used for T-ALL and MCL research .

HY-162676

SJ45566	PROTACs Src	Cancer
SJ45566 a potent and orally active PROTAC-based LCK degrader, with a DC₅₀ of 1.21 nM. SJ45566 can be used in the research for T‑Cell Acute Lymphoblastic Leukemia .

HY-175280

Lck degrader-1	Molecular Glues Src	Cancer
Lck degrader-1 (Compound 17) is a molecular glue degrader targeting lymphocyte-specific protein tyrosine kinase (LCK) (DC₅₀=23.1 nM). Lck degrader-1 is promising for research of T-cell acute lymphoblastic leukemia (T-ALL) .

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice .

HY-175281

SJ11646	PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis	Cancer
SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC₅₀ of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)

HY-179234

LD5097	PROTACs RIP kinase Apoptosis Caspase PARP	Cancer
LD5097 is a highly effective and selective PROTAC degrader targeting RIPK1. LD5097 can rapidly and efficiently downregulate RIPK1 and significantly enhance TNFα-mediated apoptosis in Jurkat cells. LD5097 significantly increases the levels of cleaved caspase-3/7 and PARP. LD5097 can be used for the study of acute T-lymphoblastic leukemia .

HY-B0078A

Dacarbazine citrate Imidazole Carboxamide citrate	Apoptosis Antibiotic	Cancer
Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma .

HY-134778

BMS-103	PD-1/PD-L1	Cancer
BMS-103 is a PDL1 inhibitor (IC₅₀ = 79.1 nM) (k_d = 44 nM). BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer .

HY-134779

BMS-142	PD-1/PD-L1	Cancer
BMS-142 is a PDL1 inhibitor (IC₅₀ = 96.7 nM) (k_d = 13.2 nM). BMS-142 can reduce the survival rate of acute T-lymphoblastic leukemia cells and ovarian cancer cells. BMS-142 can be used in research on cancers such as acute T-lymphoblastic leukemia and ovarian cancer .

HY-B0078B

Dacarbazine hydrochloride Imidazole Carboxamide hydrochloride	Antibiotic	Cancer
Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma .

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells .

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

HY-120372

BMS-871	Notch	Cancer
BMS-871 is an orally active pan-Notch inhibitor with IC₅₀ values of 4/1/4/3 nM for Notch1/2/3/4, respectively. BMS-871 significantly inhibited the proliferation of TALL-1 and MDA-MB-157 cells and demonstrated significant antitumor activity in T-acute lymphoblastic leukemia and triple-negative breast cancer xenograft models. BMS-871 can be used to study leukemia and breast cancer .

HY-P10371

PKHB1 txCD47	Reactive Oxygen Species (ROS) Thrombopoietin Receptor Mitochondrial Metabolism HSP HSV CD47	Infection Inflammation/Immunology Cancer
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8 ⁺T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia .

HY-P991328

MAb604.107	Notch	Cancer
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .

HY-13701R

Nelarabine (Standard) 506U78 (Standard); GW 506U78 (Standard); Nelzarabine (Standard)	Reference Standards Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Nelarabine (Standard) is the analytical standard of Nelarabine. This product is intended for research and analytical applications. Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL) .

HY-155188

NWP-0476	Bcl-2 Family	Neurological Disease
NWP-0476 is BCL-2/BCL-xL inhibitor. NWP-0476 has a modified structure with fine-tuned BCL-xL activity. NWP-0476 can be used for relapsed T-acute lymphoblastic leukemia (T-ALL) research .

HY-112255

J9	Glucocorticoid Receptor	Cancer
J9 is a small molecule that reverses Dexamethasone (HY-14648) resistance in T-cell acute lymphoblastic leukemia. J9 is lethal to CUTLL1 cells only in the presence of Dexamethasone. J9 inhibits CUTLL1 cell growth with an EC₅₀ of 28 μM in combination with Dexamethasone .

HY-103275R

Adaphostin (Standard) NSC 680410 (Standard)	Reference Standards Bcr-Abl Apoptosis	Cancer
Adaphostin (Standard) is the analytical standard of Adaphostin. This product is intended for research and analytical applications. Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210bcr/abl inhibitor (IC50=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-164466A

CAD204520 dihydrochloride	Calcium Channel Notch	Cancer
CAD204520 dihydrochloride, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 dihydrochloride can be used for T-ALL and MCL research .

HY-179159

Tubulin-IN-60	Microtubule/Tubulin	Cancer
Tubulin-IN-60 (Compound 4) is a tubulin polymerization inhibitor, with an IC₅₀ of 0.19 μM. Tubulin-IN-60 has anti-cancer activity against colorectal, pancreatic, T-cell acute lymphoblastic leukemia cancer .

HY-N5134A

ara-GMP ara-G monophosphate	Drug Metabolite Apoptosis	Inflammation/Immunology Cancer
ara-GMP (ara-G monophosphate) is a metabolite of Arabinosylguanine (ara-G) (HY-N0097A). ara-GMP incorporates into replicating DNA , initiates S phase-specific apoptosis. ara-GMP can be used for the research of cancer, such as T-cell acute lymphoblastic leukemia .

HY-180981

P19As	PROTACs Bcr-Abl	Cancer
P19As is a BCR-ABL PROTAC degrader based on Asciminib (HY-104010), with a DC₅₀ value of approximately 200 nM for the wild-type BCR-ABL protein. P19As can degrade the T315I mutant and exhibits potent anti-proliferative activity in BaF3-BCR-ABL (T315I) cells. P19As can be used for the study of chronic myeloid leukemia and acute lymphoblastic leukemia .

HY-180977

P19P	PROTACs Bcr-Abl	Cancer
P19P is a BCR-ABL PROTAC degrader based on Ponatinib (HY-12047), with a DC₅₀ value of approximately 20 nM for the wild-type BCR-ABL protein. P19P can effectively degrade various drug-resistant mutants such as T315I, E255K, H396R, and V468F, and exhibits potent anti-proliferative activity in BaF3-BCR-ABL (T315I) cells. P19P maintains strong inhibitory activity against ABL (T315I), with a IC₅₀ of 13.1 nM. P19P does not inhibit the formation of vascular lumens in HUVEC. P19P can be used for research on chronic myeloid leukemia and acute lymphoblastic leukemia .

HY-182081

Tubulin polymerization-IN-90	Microtubule/Tubulin Interleukin Related	Cancer
Tubulin polymerization-IN-90 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-90 disrupts tubulin polymerization by binding to the nocodazole-binding site on β-tubulin. Tubulin polymerization-IN-90 induces the release of extracellular vesicles marked by the tetraspanin CD63. Tubulin polymerization-IN-90 induces the release of IL-8 from cells. Tubulin polymerization-IN-90 reduces the viability of cancer cells. Tubulin polymerization-IN-90 can be used in the research of cancers such as acute T-lymphoblastic leukemia .

HY-185459

PCIP-1	PARP Epigenetic Reader Domain	Cancer
PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers .

HY-181653

PROTAC SKP2 Degrader-1	PROTACs E1/E2/E3 Enzyme DNA/RNA Synthesis JAK STAT Apoptosis	Cancer
PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a K_d value of 6.28 μM. PROTAC SKP2 Degrader-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degrader-1 stabilizes the expression of SOCS1 and regulates the expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degrader-1 is applicable for cancer-related research .

HY-P992275

Anti-Nicastrin Antibody (A5226A)	γ-secretase	Neurological Disease Cancer
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease .

HY-179372

Tubulin polymerization-IN-84	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-84 inhibits tubulin polymerization by targeting the colchicine-binding pocket, with anIC₅₀ = 10.9 μM. Tubulin polymerization-IN-84 shows antiproliferative activity against Jurkat, B16-F10, HCT116, and MDA-MB-231 cells (IC₅₀ = 60 nM, 380 nM, 138 nM, and 1.054 μM). Tubulin polymerization-IN-84 induces G2/M-phase arrest and apoptosis in B16-F10 cells. Tubulin polymerization-IN-84 suppresses tumor growth in a B16-F10 melanoma model and potentiates anti-tumor immunity in combination with a PD-L1 mAb for the research of T-cell acute lymphoblastic leukemia, melanoma, colon cancer, and breast cancer.

HY-P991896

AT1412 AT14-012	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells ^[1] .

Cat. No.	Product Name	Target	Research Area